ENTX — Entera Bio Income Statement
0.000.00%
Last trade - 00:00
- $70.25m
- $59.23m
- 32
- 13
- 77
- 36
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 10-K | 10-K | 10-K | 10-K |
Standards: | IFRS | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.236 | 0.365 | 0.571 | 0.134 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.026 | 0.065 | 0.198 | 0.033 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 11.7 | 11.5 | 12.8 | 13.2 | 8.89 |
Operating Profit | -11.5 | -11.2 | -12.2 | -13 | -8.89 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.8 | -11.2 | -12.2 | -12.9 | -8.86 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.8 | -11.2 | -12.2 | -13.1 | -8.89 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.8 | -11.2 | -12.2 | -13.1 | -8.89 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.8 | -11.2 | -12.2 | -13.1 | -8.89 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.889 | -0.609 | -0.466 | -0.454 | -0.306 |